Abstract Details

Title Healthcare Utilization and Costs in Narcolepsy: Findings from the Burden of Narcolepsy Disease (BOND) Study of 9,312 Patients in the United States

Topic Sleep

Presentation(s) S19 - (-)

Poster/Presentation
Number 006

Objective

Background Aside from recently published findings from the Danish National Patient Registry (Jennum et al, Sleep Med 2012;13:1086-93), there is a lack of data on the burden of illness in narcolepsy, and no large dataset in the United States has been reported.

Design/Methods MarketScan® Databases, Thomson Healthcare, Inc., were accessed to identify individuals ?18 years of age with at least one diagnosis code for narcolepsy + cataplexy (ICD9 347.0, 347.00, 347.01, 347.1, 347.10, or 347.11) continuously insured between 2006 and 2010, and controls without narcolepsy matched 5:1 on age, gender, region, and payer. Extensive sub-analyses were conducted to determine the validity of the combined database.

Results The final population included 9312 narcolepsy subjects and 46,559 controls (each group, average age of 46.1 years and 59% female). Compared with controls, narcolepsy subjects had approximately 2-fold higher annual rates of inpatient admissions (0.15 vs 0.08), emergency department visits w/o admission (0.34 vs 0.17), hospital outpatient visits (2.8 vs 1.4), other outpatient services (7.0 vs 3.2), and physician visits (11.1 vs 5.6) (all p<0.0001). The rate of total annual drug transactions was doubled in the narcolepsy group vs controls (26.4 vs 13.3; p<0.0001), including a 337% and 72% higher usage rate of narcolepsy drugs and non-narcolepsy drugs, respectively (both p<0.0001). Mean yearly costs were significantly higher in the narcolepsy group compared with controls for medical services ($8,346 vs $4,147; p<0.0001) and drugs ($3,356 vs $1,114; p<0.0001).

Conclusions Narcolepsy is associated with substantial personal and economic burdens, as indicated by significantly higher rates of healthcare utilization and medical costs. These findings in a large U.S. group of narcolepsy patients corroborate those reported in Denmark by Jennum et al (2012).

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Maurice M. Ohayon, MD, PhD, DSc (Stanford)	The institution of Dr. Ohayon has received research support from Jazz pharmaceuticals. The institution of Dr. Ohayon has received research support from Takeda Pharmaceuticals.
David Vaillancourt	David Vaillancourt has received personal compensation for serving as an employee of Automated Imaging Diagnostics. David Vaillancourt has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. The institution of David Vaillancourt has received research support from NIH. David Vaillancourt has received intellectual property interests from a discovery or technology relating to health care.
Christian Guilleminault, MD (Sleep Disorders Clinic)	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��